Anti-thymocyte Globulin/Anti-lymphocyte Globulin使用症例における副作用の検討

小林 良二; 金田 真; 渡辺 直樹; 井口 晶裕; 長 祐子; 吉田 真; 有岡 秀樹; 内藤 広行; 鹿野 高明; 石川 順一

doi:10.11406/rinketsu.40.531

Adverse Effects of Anti-thymocyte Globulin/Anti-lymphocyte Globulin Therapy

Ryoji KOBAYASHI, Makoto KANEDA, Naoki WATANABE, Akihiro IGUCHI, Yuko CHO, Makoto YOSHIDA, Hideki ARIOKA, Hiroyuki NAITO, Takaaki SHIKANO, Yorikazu ISHIKAWA

Author information

Ryoji KOBAYASHI
Department of Pediatrics, Hokkaido University School of Medicine
Makoto KANEDA
Department of Pediatrics, Hokkaido University School of Medicine
Naoki WATANABE
Department of Pediatrics, Hokkaido University School of Medicine
Akihiro IGUCHI
Department of Pediatrics, Hokkaido University School of Medicine
Yuko CHO
Department of Pediatrics, Hokkaido University School of Medicine
Makoto YOSHIDA
Department of Pediatrics, Hokkaido University School of Medicine
Hideki ARIOKA
Department of Pediatrics, Hokkaido University School of Medicine
Hiroyuki NAITO
Department of Pediatrics, Hokkaido University School of Medicine
Takaaki SHIKANO
Department of Pediatrics, Hokkaido University School of Medicine
Yorikazu ISHIKAWA
Department of Pediatrics, Hokkaido University School of Medicine

Keywords: Anti-thymocyte globulin, Anti-lymphocyte globulin, Aplastic anemia, Bone marrow transplantation, Side effect

JOURNAL RESTRICTED ACCESS

1999 Volume 40 Issue 7 Pages 531-535

DOI https://doi.org/10.11406/rinketsu.40.531

Details

Abstract

This single-centre study evaluated the adverse effects of anti-thymocyte globulin (ATG) and anti-lymphocyte globulin (ALG) as used for the treatment of aplastic anemia and/or for conditioning regimens prior to stem cell transplantation. ATG/ALG was given to 29 patients a total of 37 times. The incidence of adverse effects was 62.1% (23/37), and fever was the most frequent adverse effect. Therapy was discontinued in only 4 patients (10.8%) due to severe adverse effects. Adverse effects occurred more frequently with ATG (rabbit-derived) than with ALG (horse-derived). Seven patients underwent 2 or 3 cycles of ATG/ALG therapy, for a combined total of 8 times; 6 of those patients (75% (6/8)) experienced adverse effects. Shorter intervals between repeated cycles of therapy appeared to heighten the risk of adverse reactions.

Corresponding author

Register with J-STAGE for free!